AUB ScholarWorks

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

Show simple item record Bashshur Z.F. Bazarbachi A. Schakal A. Haddad Z.A. El Haibi C.P. Noureddin B.N.
dc.contributor.editor Jul-2006 2017-10-05T15:49:16Z 2017-10-05T15:49:16Z 2006
dc.identifier 10.1016/j.ajo.2006.02.037
dc.identifier.issn 00029394
dc.description.abstract Purpose: To investigate the efficacy and safety of intravitreal bevacizumab for managing choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Design: Prospective interventional case series. Methods: Seventeen eyes of 17 patients with subfoveal CNV due to AMD participated in this study at the American University of Beirut Ophthalmology Clinics. All patients had failed, refused, or were not eligible for photodynamic therapy. All eyes received a baseline eye examination, which included best-corrected visual acuity (BCVA), dilated fundus examination, ocular coherence tomography (OCT) imaging, and fluorescein angiography. An intravitreal injection of bevacizumab (2.5 mg-0.1 ml) was given at baseline and followed by two additional injections at four-week intervals. BCVA, OCT, and fluorescein angiography were repeated four weeks after each injection. Main outcome measures were improvement in BCVA and central retinal thickness (CRT). Results: Mean baseline BCVA was 20-252 (median 20-200), and baseline CRT was 362 μm (median 350 μm). Improvement in VA and CRT occurred by the fourth week. At 12 weeks, mean BCVA was 20-76 (P .001) and median BCVA was 20-50 (P .001). Both mean and median CRT decreased to 211 μm (P .001). Thirteen (76percent) of 17 eyes had total resolution of subretinal fluid, and four eyes (24percent) had BCVA better than 20-50. No systemic or ocular side effects were noted at any time. Conclusion: Eyes with CNV due to AMD treated with intravitreal bevacizumab had marked anatomic and visual improvement. Further studies are necessary to confirm the long-term efficacy and safety of this treatment. © 2006 Elsevier Inc. All rights reserved.
dc.format.extent Pages: (1-9)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: American Journal of Ophthalmology; Publication Year: 2006; Volume: 142; no. 1; Pages: (1-9);
dc.source Scopus
dc.title Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration
dc.type Article
dc.contributor.affiliation Bashshur, Z.F., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Schakal, A., Department of Ophthalmology, Hotel Dieu de France (St Joseph University), Beirut, Lebanon
dc.contributor.affiliation Haddad, Z.A., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation El Haibi, C.P., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Noureddin, B.N., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Bashshur, Z.F.; Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Bashshur, ZF
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorInitials Schakal, A
dc.contributor.authorInitials Haddad, ZA
dc.contributor.authorInitials El Haibi, CP
dc.contributor.authorInitials Noureddin, BN
dc.contributor.authorReprintAddress Bashshur, ZF (reprint author), Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236,B11, Beirut, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016-S0002-9440(10)65138-3; Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006-jmbi.1999.3192; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; EUGENE WM, 2005, CAN J OPHTHALMOL, V40, P352; Fernando NH, 2003, SEMIN ONCOL, V30, P39, DOI 10.1016-S0093-7754(03)00124-6; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056-NEJMoa042760; *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109; BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176; Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016-j.ophtha.2005.02.007; Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161; Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093-toxsci-52.1.101; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177-019262339902700507; Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517-14712598.5.7.997; Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016-j.ophtha.2005.01.043; Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074-jbc.273.32.20556; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307; United States Pharmacopoeia, US PHARM; van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001-jama.293.12.1509; Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007-s10456-004-8272-2
dc.description.citedCount 248
dc.description.citedTotWOSCount 216
dc.description.citedWOSCount 201
dc.format.extentCount 9
dc.identifier.coden AJOPA
dc.identifier.pubmedID 16815245
dc.identifier.scopusID 33745418105
dc.publisher.address 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
dc.relation.ispartOfISOAbbr Am. J. Ophthalmol.
dc.relation.ispartOfIssue 1
dc.relation.ispartofPubTitle American Journal of Ophthalmology
dc.relation.ispartofPubTitleAbbr Am. J. Ophthalmol.
dc.relation.ispartOfVolume 142
dc.source.ID WOS:000239079100001
dc.type.publication Journal
dc.subject.otherChemCAS bevacizumab, 216974-75-3
dc.subject.otherChemCAS ciprofloxacin, 85721-33-1
dc.subject.otherChemCAS lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9
dc.subject.otherChemCAS tobramycin, 32986-56-4
dc.subject.otherChemCAS Angiogenesis Inhibitors
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS bevacizumab
dc.subject.otherChemCAS Vascular Endothelial Growth Factor A
dc.subject.otherChemCAS vascular endothelial gro
dc.subject.otherIndex bevacizumab
dc.subject.otherIndex ciprofloxacin
dc.subject.otherIndex lidocaine
dc.subject.otherIndex tobramycin
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex cataract
dc.subject.otherIndex clinical article
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex endophthalmitis
dc.subject.otherIndex eye
dc.subject.otherIndex eye disease
dc.subject.otherIndex female
dc.subject.otherIndex fluorescence angiography
dc.subject.otherIndex human
dc.subject.otherIndex inflammation
dc.subject.otherIndex injection
dc.subject.otherIndex intraocular pressure abnormality
dc.subject.otherIndex male
dc.subject.otherIndex ophthalmoscopy
dc.subject.otherIndex optical coherence tomography
dc.subject.otherIndex photodynamic therapy
dc.subject.otherIndex priority journal
dc.subject.otherIndex retina
dc.subject.otherIndex retina detachment
dc.subject.otherIndex retina macula age related degeneration
dc.subject.otherIndex subretinal fluid
dc.subject.otherIndex subretinal neovascularization
dc.subject.otherIndex systemic disease
dc.subject.otherIndex thromboembolism
dc.subject.otherIndex vision
dc.subject.otherIndex visual acuity
dc.subject.otherIndex visual impairment
dc.subject.otherIndex vitreous hemorrhage
dc.subject.otherIndex Aged
dc.subject.otherIndex Angiogenesis Inhibitors
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Choroidal Neovascularization
dc.subject.otherIndex Female
dc.subject.otherIndex Fluorescein Angiography
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Humans
dc.subject.otherIndex Injections
dc.subject.otherIndex Macular Degeneration
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Retina
dc.subject.otherIndex Tomography, Optical Coherence
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Vascular Endothelial Growth Factor A
dc.subject.otherIndex Visual Acuity
dc.subject.otherIndex Vitreous Body
dc.subject.otherKeywordPlus ENDOTHELIAL GROWTH-FACTOR
dc.subject.otherKeywordPlus RANDOMIZED CLINICAL-TRIALS
dc.subject.otherKeywordPlus LASER PHOTOCOAGULATION
dc.subject.otherKeywordPlus PHOTODYNAMIC THERAPY
dc.subject.otherKeywordPlus COLORECTAL-CANCER
dc.subject.otherKeywordPlus UNITED-STATES
dc.subject.otherKeywordPlus VERTEPORFIN
dc.subject.otherKeywordPlus ANTIBODY
dc.subject.otherKeywordPlus PHARMACOKINETICS
dc.subject.otherKeywordPlus INHIBITION
dc.subject.otherWOS Ophthalmology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account